The use of thermal ablation in diverse cervical cancer "screen-and-treat" service platforms in Zambia.

cervical cancer prevention cervical dysplasia cold coagulation low- and middle-income countries screen-and-treat thermal ablation

Journal

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174

Informations de publication

Date de publication:
Apr 2022
Historique:
revised: 17 06 2021
received: 07 02 2021
accepted: 30 06 2021
pubmed: 2 7 2021
medline: 25 3 2022
entrez: 1 7 2021
Statut: ppublish

Résumé

Thermal ablation (TA) was implemented in public sector cervical cancer prevention services in Zambia in 2012. Initially introduced as a treatment modality in primary healthcare clinics, it was later included in mobile outreach campaigns and clinical research trials. We report the feasibility, acceptability, safety, and provider uptake of TA in diverse clinical contexts. Screening services based on visual inspection with acetic acid were offered by trained nurses to non-pregnant women aged 25-59 years. Women with a type 1 transformation zone (TZ) were treated with same-visit TA. Those with a type 2 or 3 TZ, or suspicious for cancer, were managed with same-visit electrosurgical excision or punch biopsy, respectively. A provider survey was conducted. Between 2012 and 2020, 2123 women were treated with TA: primary healthcare clinics, n = 746; mobile outreach clinics, n = 1127; research clinics, n = 250. Of the 996 women treated in primary healthcare and research clinics, 359 (48%) were HIV positive. Mild cramping during treatment was the most common adverse effect. No treatment interruptions occurred. No major complications were reported in the early (6 weeks) follow-up period. Providers expressed an overwhelming preference for TA over cryotherapy. TA was feasible, safe, and acceptable in diverse clinical contexts. It was the preferred ablation method of providers when compared with cryotherapy.

Identifiants

pubmed: 34197624
doi: 10.1002/ijgo.13808
doi:

Substances chimiques

Acetic Acid Q40Q9N063P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-89

Subventions

Organisme : US National Institute of Health
ID : 1UH2CA202721-01
Organisme : University of North Carolina
ID : 5T32HD075731-05
Organisme : University of Washington
ID : 5T32CA009515-34

Informations de copyright

© 2021 International Federation of Gynecology and Obstetrics.

Références

World Health Organization, WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization; 2013. p. 1 online resource (1 PDF file (xv, 40 pages)).
World Health Organization. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva: World Health Organization: 2019. p. 1 online resource.
Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2013;120(3):218-223.
Dolman L, Sauvaget C, Muwonge R, et al. Meta-analysis of the efficacy of cold coagulation as a treatment method for cervical intraepithelial neoplasia: a systematic review. BJOG. 2014;121(8):929-942.
Randall TC, Sauvaget C, Muwonge R, et al. Worthy of further consideration: an updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019;118:81-91.
Pinder LF, Parham GP, Basu P, et al. Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. Lancet Oncol. 2020;21(1):175-184.
Castle PE, Murokora D, Perez C, et al. Treatment of cervical intraepithelial lesions. Int J Gynaecol Obstet. 2017;138(Suppl 1):20-25.
Oga EA, Brown JP, Brown C, et al. Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. BMC Womens Health. 2016;16:25.
Campbell C, Kafwafwa S, Brown H, et al. Use of thermo-coagulation as an alternative treatment modality in a ‘screen-and-treat’ programme of cervical screening in rural Malawi. Int J Cancer. 2016;139(4):908-915.
Viviano M, Kenfack B, Catarino R, et al. Feasibility of thermocoagulation in a screen-and-treat approach for the treatment of cervical precancerous lesions in sub-Saharan Africa. BMC Womens Health. 2017;17(1):2.
Joshi S, Kulkarni V, Darak T, et al. Cervical cancer screening and treatment of cervical intraepithelial neoplasia in female sex workers using "screen and treat" approach. Int J Womens Health. 2015;7:477-483.
Chigbu CO, Onwudiwe EN, Onyebuchi AK. Thermo-coagulation versus cryotherapy for treatment of cervical precancers: a prospective analytical study in a low-resource African setting. J Obstet Gynaecol Res. 2020;46(1):147-152.
Kunckler M, Schumacher F, Kenfack B, et al. Cervical cancer screening in a low-resource setting: a pilot study on an HPV-based screen-and-treat approach. Cancer Med. 2017;6(7):1752-1761.
Sandoval M, Slavkovsky R, Bansil P, et al. Acceptability and safety of thermal ablation for the treatment of precancerous cervical lesions in Honduras. Trop Med Int Health. 2019;24(12):1391-1399.
International Agency for Research on Cancer. GLOBOCAN. Estimated cancer incidence. Mortality and Prevalence Worldwide in 2018. 2018.
Parham GP, Mwanahamuntu MH, Kapambwe S, et al. Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in Zambia. PLoS One. 2015;10(4):e0122169.
Kapambwe S, Parham G, Mwanahamuntu M, et al. Innovative approaches to promoting cervical health and raising cervical cancer awareness by use of existing cultural structures in resource-limited countries: experiences with traditional marriage counseling in Zambia. Global Health Promotion. 2013;20(4):57-64.
Kapambwe S, Mwanahamuntu M, Pinder LF, et al. Partnering with traditional Chiefs to expand access to cervical cancer prevention services in rural Zambia. Int J Gynaecol Obstet. 2019;144(3):297-301.
Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, et al. Implementation of ‘see-and-treat’ cervical cancer prevention services linked to HIV care in Zambia. AIDS. 2009;23(6):N1-5.
Mwanahamuntu MH, Sahasrabuddhe VV, Blevins M, et al. Utilization of cervical cancer screening services and trends in screening positivity rates in a ‘Screen-And-Treat’ program integrated with HIV/AIDS Care in Zambia. PLoS One. 2013;8(9):e74607.
Parham GP, Mwanahamuntu MH, Sahasrabuddhe VV, et al. Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness. HIV Ther. 2010;4(6):703-722.
Fergusson IL, Craft IL. A new "Cold coagulator" for use in the outpatient treatment of cervical erosion. J Obstet Gynaecol Br Commonw. 1974;81(4):324-327.
Basu P, Mittal S, Bhadra Vale D, et al. Secondary prevention of cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2018;47:73-85.
Maza M, Schocken CM, Bergman KL, et al. cervical precancer treatment in low- and middle-income countries: a technology overview. J Glob Oncol. 2017;3(4):400-408.

Auteurs

Mulindi Mwanahamuntu (M)

Department of Obstetrics and Gynecology, Women and Newborn Hospital, Lusaka, Zambia.

Sharon Kapambwe (S)

Zambia Ministry of Health, Cancer Control, Lusaka, Zambia.

Leeya F Pinder (LF)

Department of Obstetrics and Gynecology, Women and Newborn Hospital, Lusaka, Zambia.
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.

Jane Matambo (J)

Center for Infectious Disease Research in Zambia, Cervical Cancer Prevention Program, Lusaka, Zambia.

Susan Chirwa (S)

Center for Infectious Disease Research in Zambia, Cervical Cancer Prevention Program, Lusaka, Zambia.

Samson Chisele (S)

Department of Obstetrics and Gynecology, Women and Newborn Hospital, Lusaka, Zambia.

Partha Basu (P)

International Agency for Research on Cancer, WHO Screening Group, Early Detection and Prevention Section, Lyon, France.

Walter Prendiville (W)

International Agency for Research on Cancer, WHO Screening Group, Early Detection and Prevention Section, Lyon, France.

Rengaswamy Sankaranarayanan (R)

International Agency for Research on Cancer, WHO Screening Group, Early Detection and Prevention Section, Lyon, France.

Groesbeck P Parham (GP)

Department of Obstetrics and Gynecology, Women and Newborn Hospital, Lusaka, Zambia.
Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH